{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:44:51Z","timestamp":1763621091673,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/n\/a","name":"Richard V. Lee Award NASOM North American Society of Obstetrics in Medicine","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/n\/a","name":"Cooper Foundation","doi-asserted-by":"publisher","award":["402200"],"award-info":[{"award-number":["402200"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/n\/a","name":"Cooper Medical School of Rowan University","doi-asserted-by":"publisher","award":["800002"],"award-info":[{"award-number":["800002"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00431-021-04260-3","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:03:55Z","timestamp":1642896235000},"page":"1763-1766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Paclitaxel use in pregnancy: neonatal follow-up of infants with positive detection of intact paclitaxel and metabolites in meconium at birth"],"prefix":"10.1007","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-3367","authenticated-orcid":false,"given":"Elyce H.","family":"Cardonick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andie E.","family":"O\u2019Laughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha C.","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay T.","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serwaa","family":"Akoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,23]]},"reference":[{"key":"4260_CR1","doi-asserted-by":"crossref","unstructured":"Peccatori F, Azim HA Jr, Orecchia R et al (2013) Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 24 (suppl 6) vi 160\u2013170","DOI":"10.1093\/annonc\/mdt199"},{"key":"4260_CR2","doi-asserted-by":"crossref","unstructured":"Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M et al (2006) Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107(6):1219","DOI":"10.1002\/cncr.22081"},{"issue":"3","key":"4260_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/COC.0b013e3181a44ca9","volume":"33","author":"E Cardonick","year":"2010","unstructured":"Cardonick E, Usmani A, Ghaffar S (2010) Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol 33(3):221\u2013228","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"4260_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3816\/CLM.2001.n.023","volume":"2","author":"A Aviles","year":"2001","unstructured":"Aviles A, Neri N (2001) Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2(3):173\u2013177","journal-title":"Clin Lymphoma"},{"issue":"19","key":"4260_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1508913","volume":"373","author":"F Amant","year":"2015","unstructured":"Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I et al (2015) Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med 373(19):1824\u20131834","journal-title":"N Engl J Med"},{"key":"4260_CR6","doi-asserted-by":"crossref","unstructured":"Cardonick EH, Gringlas MB, Hunter K, Greenspan J (2015) Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol 212(5):658 e1\u20138","DOI":"10.1016\/j.ajog.2014.11.032"},{"key":"4260_CR7","doi-asserted-by":"crossref","unstructured":"Cardonick E, Broadrup R, Xu P, Doan MT, Jiang H, Snyder NW (2019) Preliminary results of identification and quantification of paclitaxel and its metabolites in human meconium from newborns with gestational chemotherapeutic exposure. PLoS One 14(2):e0211821","DOI":"10.1371\/journal.pone.0211821"},{"key":"4260_CR8","doi-asserted-by":"crossref","unstructured":"Berveiller P, Vinot C, Mir O, Broutin S, Deroussent A, Seck A et al (2012) Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model. Am J Obstet Gynecol 207(6):514 e1\u20137","DOI":"10.1016\/j.ajog.2012.10.007"},{"issue":"9","key":"4260_CR9","first-page":"1456","volume":"20","author":"KV Calsteren","year":"2010","unstructured":"Calsteren KV, Verbesselt R, Devlieger R, De Catte L, Chai DC, Van Bree R et al (2010) Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer 20(9):1456\u20131464","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"4260_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1517\/17425255.3.3.331","volume":"3","author":"P Myllynen","year":"2007","unstructured":"Myllynen P, Pasanen M, Vahakangas K (2007) The fate and effects of xenobiotics in human placenta. Expert Opin Drug Metab Toxicol 3(3):331\u2013346","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4260_CR11","unstructured":"Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137e43"},{"key":"4260_CR12","doi-asserted-by":"crossref","unstructured":"Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104:1441e7","DOI":"10.1172\/JCI7963"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04260-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-021-04260-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04260-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:17:40Z","timestamp":1648559860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-021-04260-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["4260"],"URL":"https:\/\/doi.org\/10.1007\/s00431-021-04260-3","relation":{},"ISSN":["1432-1076"],"issn-type":[{"type":"electronic","value":"1432-1076"}],"subject":[],"published":{"date-parts":[[2022,1,23]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Cooper Health System Institutional Research Board and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Women diagnosed with cancer during pregnancy were offered enrollment in a multicenter cohort study registered with clinicaltrials.gov NCT02749474 that collects diagnostic and treatment information as well as neonatal well-being for this unique cohort of patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants gave their informed consent to participate in this study and have de-identified information used in publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}